ALTIMMUNE, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ALTIMMUNE, INC. (ALT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$138.21 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-03.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-05-03
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$138.21M.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $84.89M.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $45.95M.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was $8.92M, a 232.07% increase year-over-year.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $138.43M.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$3.07M, a 137.65% decline from fiscal 2014.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $8.16M.
- ALTIMMUNE, INC. cash and cash equivalents, period increase (decrease) for fiscal 2013 was -$2.22M, a 251.60% decline from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-03-31 | -$138.21M 10-Q · filed 2017-05-03 | -$53.32M derived: sum of 2 quarters · filed 2017-05-03 | -$7.38M derived: sum of 3 quarters · filed 2017-05-03 | $1.55M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-12-31 | $84.89M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $130.84M derived: sum of 2 quarters · filed 2017-03-14 | $139.76M derived: sum of 3 quarters · filed 2017-03-14 | $138.43M 10-K · filed 2017-03-14 |
| 2016-09-30 | $45.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $54.87M derived: sum of 2 quarters · filed 2016-11-04 | $53.54M 10-Q · filed 2016-11-04 | $51.72M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-06-30 | $8.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $7.59M 10-Q · filed 2016-08-04 | $5.77M derived: sum of 3 quarters · filed 2017-05-03 | $4.75M derived: sum of 4 quarters · filed 2017-05-03 |
| 2016-03-31 | -$1.33M 10-Q · filed 2017-05-03 | -$3.15M derived: sum of 2 quarters · filed 2017-05-03 | -$4.18M derived: sum of 3 quarters · filed 2017-05-03 | -$1.49M derived: sum of 4 quarters · filed 2017-05-03 |
| 2015-12-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$2.84M derived: sum of 2 quarters · filed 2017-03-14 | -$155.14K derived: sum of 3 quarters · filed 2017-03-14 | -$3.07M 10-K · filed 2017-03-14 |
| 2015-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.66M derived: sum of 2 quarters · filed 2016-11-04 | -$1.25M 10-Q · filed 2016-11-04 | -$2.23M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$231.51K 10-Q · filed 2016-08-04 | -$1.21M derived: sum of 3 quarters · filed 2017-03-14 | $7.15M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | -$2.92M 10-Q · filed 2016-05-09 | -$3.90M derived: sum of 2 quarters · filed 2017-03-14 | $4.46M derived: sum of 3 quarters · filed 2017-03-14 | $6.19M derived: sum of 4 quarters · filed 2017-03-14 |
| 2014-12-31 | -$977.04K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $7.38M derived: sum of 2 quarters · filed 2017-03-14 | $9.11M derived: sum of 3 quarters · filed 2017-03-14 | $8.16M 10-K · filed 2017-03-14 |
| 2014-09-30 | $8.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $10.09M derived: sum of 2 quarters · filed 2015-11-06 | $9.14M 10-Q · filed 2015-11-06 | $3.68M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $784.10K 10-Q · filed 2015-08-05 | -$4.68M derived: sum of 3 quarters · filed 2016-03-11 | -$4.52M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$946.26K 10-Q · filed 2015-05-07 | -$6.41M derived: sum of 2 quarters · filed 2016-03-11 | -$6.26M derived: sum of 3 quarters · filed 2016-03-11 | -$3.34M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$5.31M derived: sum of 2 quarters · filed 2016-03-11 | -$2.39M derived: sum of 3 quarters · filed 2016-03-11 | -$2.22M 10-K · filed 2016-03-11 |
| 2013-09-30 | $153.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $3.07M derived: sum of 2 quarters · filed 2014-11-06 | $3.24M 10-Q · filed 2014-11-06 | $1.22M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $3.09M 10-Q · filed 2014-08-05 | $1.06M derived: sum of 3 quarters · filed 2015-03-11 | $4.01M derived: sum of 4 quarters · filed 2015-03-11 |
| 2013-03-31 | $171.89K 10-Q · filed 2014-05-08 | -$1.85M derived: sum of 2 quarters · filed 2015-03-11 | $1.10M derived: sum of 3 quarters · filed 2015-03-11 | -$2.43M derived: sum of 4 quarters · filed 2015-03-11 |
| 2012-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $924.60K derived: sum of 2 quarters · filed 2015-03-11 | -$2.60M derived: sum of 3 quarters · filed 2015-03-11 | $1.46M 10-K · filed 2015-03-11 |
| 2012-09-30 | $2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$577.86K derived: sum of 2 quarters · filed 2013-11-07 | $3.49M 10-Q · filed 2013-11-07 | $4.32M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-06-30 | -$3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $540.15K 10-Q · filed 2013-08-08 | $1.37M derived: sum of 3 quarters · filed 2014-03-11 | -$2.38M derived: sum of 4 quarters · filed 2014-03-11 |
| 2012-03-31 | $4.07M 10-Q · filed 2013-05-08 | $4.90M derived: sum of 2 quarters · filed 2014-03-11 | $1.14M derived: sum of 3 quarters · filed 2014-03-11 | $5.60M derived: sum of 4 quarters · filed 2014-03-11 |
| 2011-12-31 | $830.70K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | -$2.92M derived: sum of 2 quarters · filed 2014-03-11 | $1.53M derived: sum of 3 quarters · filed 2014-03-11 | -$548.56K 10-K · filed 2014-03-11 |
| 2011-09-30 | -$3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $697.83K derived: sum of 2 quarters · filed 2012-11-06 | -$1.38M 10-Q · filed 2012-11-06 | $7.69M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-06-30 | $4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $2.38M 10-Q · filed 2012-08-07 | $11.44M derived: sum of 3 quarters · filed 2013-03-14 | $13.48M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-03-31 | -$2.08M 10-Q · filed 2012-05-10 | $6.99M derived: sum of 2 quarters · filed 2013-03-14 | $9.03M derived: sum of 3 quarters · filed 2013-03-14 | |
| 2010-12-31 | $9.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | $11.10M derived: sum of 2 quarters · filed 2013-03-14 | $9.11M 10-K · filed 2013-03-14 | |
| 2010-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $44.21K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$1.99M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |